For All The Palace Intrigue, Rebate Rule, IPI Go To OMB For Review

For all the rumors of political infighting, the two cornerstones of the Trump administration’s blueprint on drug pricing are in the final phase for review.

Global Marekt Price tag
Proposals for an International Pricing Index in Medicare Part B and for eliminating the safe harbor for drug rebates in Medicare Part D and Medicaid managed care are in the final stage of regulatory review. • Source: Shutterstock

The Trump administration’s two signature efforts to address drug prices and out of pocket costs are now pending review at the White House Office of Management and Budget.

The final rule eliminating the safe harbor for drug rebates in Medicare Part D and Medicaid managed care was received by OMB on 10 June. Prior to that, the Centers for Medicare and Medicaid Services formally notified Medicare Part D insurers that there would be no changes to the rebate safe harbor before 2020 bids to provide drug benefits were due 3 June

More from Pricing Debate

More from Market Access